MYLAN BENEFITING FROM COPAXONE $MYL $TEVA
This post was just published on ZYX Buy Change Alert. MYL is benefiting from invalidation of TEVA patent on Copaxone, an MS drug. The new buy zone is $32 to $35.57. Recommended position size is 35% to 40%. The stock is trading at $38.40 as of this writing. What To Do Now Those in the stock may continue to hold. Those not in the stock may consider waiting for a dip into the buy zone. You are receiving less than 2% of the content from our paid services …TO RECEIVE REMAINING 98%, TAKE A FREE TRIAL TO PAID SERVICES. Please click here